• Wondering if McKesson is still worth buying after such a big run, or if the value has already been priced in? This breakdown is designed to help you decide with confidence.
• After climbing 45.8% year to date and 43.2% over the last year, the stock has cooled slightly, with a 1.9% gain in the past week and a 4.7% pullback over the last month. This hints at both strong momentum and rising questions about upside from here.
• Recent headlines have focused on McKesson expanding its role in pharmaceutical distribution and specialty care, including deeper partnerships with drugmakers and health systems. This reinforces the market's view of it as critical infrastructure in US healthcare. At the same time, investors are watching regulatory and reimbursement developments that could reshape margins across the drug supply chain, adding nuance to the bullish narrative.
• Right now, McKesson scores a 4/6 valuation check score, suggesting it looks undervalued on several fronts but not all. The rest of this article will unpack those different valuation lenses, and we will finish by exploring a more complete way to think about what this stock is really worth over the long term.

Approach 1: McKesson Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow (DCF) model estimates what a business is worth today by projecting the cash it could generate in the future and then discounting those cash flows back to the present.

For McKesson, the latest twelve month Free Cash Flow is about $6.0 billion. Analysts and extrapolated estimates suggest this could grow to roughly $8.7 billion by 2035, with projections of around $7.2 billion by 2030 as growth moderates over time. Simply Wall St uses a 2 Stage Free Cash Flow to Equity model, combining analyst forecasts for the next few years with longer term trend assumptions to build a ten year cash flow path.

Discounting those projected cash flows back to today yields an estimated intrinsic value of about $1,399 per share. Compared with the current market price, the model implies McKesson is trading at roughly a 41.0% discount, indicating meaningful upside if the cash flow story plays out as expected.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests McKesson is undervalued by 41.0%. Track this in your watchlist or portfolio, or discover 908 more undervalued stocks based on cash flows.

Approach 2: McKesson Price vs Earnings

For established, profitable companies like McKesson, the price to earnings multiple is a practical way to judge valuation because it links the share price directly to the profits that shareholders ultimately rely on. In general, faster earnings growth and lower perceived risk justify a higher normal or fair PE ratio, while slower growth or higher uncertainty tend to compress it.

McKesson currently trades at about 25.3x earnings, which is slightly above the broader Healthcare sector average of around 23.6x but below its peer group average near 28.4x. Simply Wall St also estimates a Fair Ratio of roughly 33.0x for McKesson, which is a proprietary view of what its PE should be once you factor in its earnings growth outlook, margins, industry positioning, size, and risk profile.

This Fair Ratio is more tailored than a straight comparison with sector or peer averages, because it adjusts for McKesson specific strengths and risks rather than assuming it should look like a typical Healthcare stock. With the shares trading well below the 33.0x Fair Ratio, the preferred multiple perspective points to McKesson being undervalued on earnings.

Result: UNDERVALUED

PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1457 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your McKesson Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let's introduce you to Narratives, a simple framework on Simply Wall St's Community page. It lets you turn your view of McKesson's story into a set of revenue, earnings, and margin assumptions, link those to a dynamic forecast and Fair Value estimate, and then compare that Fair Value with the current share price to decide whether to buy, hold, or sell. The model automatically updates as new news or earnings arrive and allows room for very different perspectives. For example, one investor might focus on automation, specialty pharma growth, and a Fair Value near $939 per share, while another emphasizes regulatory risk and margin pressure and sets a Fair Value closer to $640, even though they are looking at the same company and data.

Do you think there's more to the story for McKesson? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.